The results of the multicentre, open-label IABP-SHOCK II trial showed that intra-aortic balloon pump (IABP) counterpulsation did not reduce 30-day and 1-year mortality in patients with acute myocardial infarction (MI) and cardiogenic shock undergoing early revascularization. A new follow-up report of the study shows that IABP also did not reduce 6-year mortality in these patients. A total of 600 patients with acute MI and cardiogenic shock were randomly allocated to receive or not receive IABP support; analysis of the clinical outcomes of 591 of these patients at long-term follow-up revealed no between-group differences in all-cause mortality and in any other secondary outcome variables such as recurrent MI, stroke or new revascularization procedures. These data support the current guideline recommendations to not use IABP routinely.
References
Original article
Thiele, H. et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABP-SHOCK II trial. Circulation https://doi.org/10.1161/CIRCULATIONAHA.118.038201 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Le Bras, A. No long-term benefit of IABP in cardiogenic shock. Nat Rev Cardiol 16, 3 (2019). https://doi.org/10.1038/s41569-018-0136-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-018-0136-3